According to the IPO arrangement, six new shares will be subscribed next week, including four on the science and innovation board and two on the gem.
The new stock of science and innovation board Rendu biology subscribed next Monday is known as the first stock of A-share RNA diagnosis . The subscription of Rendu biological Dingge only needs to be matched with the market value of 25000 yuan in Shanghai. The upper limit of online issuance and subscription is only 2500 shares, or it may become one of the most difficult new shares to win the lot this year.
In addition, guanghuaxin, the new chief stock of the science and technology innovation board, which will be subscribed next Wednesday, is known as the first share of A-share laser chips. Minglida, the new share of the gem to be subscribed next Friday, is a supplier of Hangzhou Hikvision Digital Technology Co.Ltd(002415) , Huawei, and is worthy of attention.
rna diagnosis: the first stock will be renewed tomorrow
Rendu biology, a new share of the science and Innovation Board subscribed next Monday, is a leading enterprise in RNA molecular diagnosis in China, known as the first share of A-share RNA diagnosis.
The issuing price of Rendu biology is 72.65 yuan / share, the issuing price earnings ratio is 54.54 times, and the price earnings ratio of the reference industry is 35.4 times. Dingge’s subscription needs to be matched with the market value of 25000 yuan in Shanghai.
The online issuance and subscription limit of Rendu biology is only 2500 shares, which is the lowest online issuance and subscription limit of new shares this year. Generally speaking, the online issuance of new shares with a lower subscription ceiling, in which the signing rate is also relatively low. Therefore, Rendu biology may become one of the most difficult new shares to win the lot this year.
Rendu biology in the first signing of China needs to pay 36300 yuan. After the listing of Rendu biology, if the increase can reach 140%, the single signature profit can reach 50000 yuan, and if the increase can reach 280%, the single signature profit can reach 100000 yuan.
However, from the performance of new shares listed on the science and Innovation Board since this year, only one new share of Jingke energy increased by more than 100% on the first day of listing, and 22 new shares increased by an average of 12.83% on the first day of listing. There are three new shares on the science and innovation board with a single signature profit of more than 10000 yuan. Huaqin technology ranks first with 35200 yuan. The single signature profits of Salem biology and chuangyao technology are 11100 yuan and 10800 yuan respectively.
Statistics show that Rendu biology is one of the first batch of life science enterprises focusing on RNA constant temperature amplification technology and products in China. It plans to issue 10 million shares this time, and plans to raise 701 million yuan. The raised funds will be used for “research and development project of industrialization of precision diagnostic reagents and intelligent devices” and “marketing network construction project”. The actual net fund-raising of Rendu biology was 653 million yuan.
Rongchang biology, the new share of the science and innovation board to be purchased next Tuesday, is an innovative biopharmaceutical enterprise with a global vision. Dingge’s subscription needs to be matched with the Shanghai market value of 85000 yuan.
The new stock changguanghuaxin of the science and innovation board applied for next Wednesday is the leader of semiconductor laser chips in China and is considered to be the first share of A-share laser chips . Dingge’s application needs to be matched with the market value of Shanghai Stock Exchange of 55000 yuan. Tianyi medical, a new share of gem subscribed on the same day, is a comprehensive service provider of medical consumables. Dingge’s subscription needs to be matched with a market value of 40000 yuan in Shenzhen.
Zhongfu Shenying, the new share of the science and innovation board to be purchased next Thursday, is a leader in the industrialization of domestic carbon fiber. Dingge’s subscription needs to be matched with the market value of 140000 yuan in Shanghai.
Minglida, the gem new share subscribed next Friday, is a manufacturer of precision structural parts. Dingge’s subscription needs to be matched with the Shenzhen market value of 65000 yuan. Minglida is a supplier of Hangzhou Hikvision Digital Technology Co.Ltd(002415) , Huawei.
Minglida disclosed in the prospectus that in the photovoltaic field, the company’s customers include solardedge, SMA, Tesla, Sungrow Power Supply Co.Ltd(300274) and other industry-leading companies; In the field of security, the company’s customers include Hangzhou Hikvision Digital Technology Co.Ltd(002415) , Huawei, axis, Bosch and other well-known enterprises at home and abroad; In the automotive field, the company’s customers include Byd Company Limited(002594) , BAIC new energy, Contemporary Amperex Technology Co.Limited(300750) , grammer and other well-known automobile and auto parts manufacturers at home and abroad; In the field of consumer electronics, the company’s customers include Intel, NEC, Honeywell, Scud group, etc.
list of new share subscription information next week
Rendu biology: R & D, production and sales of molecular diagnostic reagents and equipment integrated products based on RNA real-time fluorescence constant temperature amplification (SAT) patented technology platform, focusing on providing solutions for accurate diagnosis, effective prevention and control and personalized diagnosis and treatment of pathogens in reproductive, respiratory, digestive, blood, food, environmental safety and other fields
Rongchang biology: focuses on the field of therapeutic antibody drugs such as antibody drug conjugate (ADC), antibody fusion protein, monoclonal antibody and double antibody. The company is committed to discovering, developing and commercializing innovative and distinctive first in class and best in class biological drugs. Guided by the creation of drug clinical value, the company provides safe, effective and accessible clinical solutions for major diseases such as autoimmune diseases, tumor diseases and ophthalmic diseases, so as to meet a large number of unmet clinical needs
Tianyi medical: mainly engaged in the R & D, production and sales of medical devices such as medical polymer consumables in the field of blood purification and ward nursing
Changguang Huaxin: focuses on the R & D, design and manufacturing of semiconductor laser chips
Zhongfu Shenying: specializes in carbon fiber R & D, production and sales
minglida: mainly engaged in the design, R & D, production and sales of precision structural parts and molds
